Stefania Zamboni
University of Brescia
DissectionInternal medicineRadiologyUrologySurgeryOncologyResectionStage (cooking)PathologicalCystectomyChemotherapyProstatectomyProstate cancerBladder cancerLymph nodeIn patientUrothelial carcinomaConfidence intervalProportional hazards modelMedicineCohort
88Publications
9H-index
210Citations
Publications 83
Newest
#1Alberto MartiniH-Index: 27
#2Luca AfferiH-Index: 2
Last. Marco MoschiniH-Index: 27
view all 23 authors...
PURPOSE Presently, major guidelines do not provide specific recommendations on oncologic surveillance for patients who harbor VH BCa at radical cystectomy. We aimed to create a personalized follow-up scheme that dynamically weighs OCM versus the risk of recurrence for VH BCa, and to compare it with a similar one for pUC. METHODS Within a multi-institutional registry, 528 and 1,894 patients with VH BCa and pUC, were identified. The Weibull regression was used to detect the time points after which...
Source
#1Matteo Ferro (IEO: European Institute of Oncology)H-Index: 29
#2Ottavio De Cobelli (IEO: European Institute of Oncology)H-Index: 31
Last. Carlo BuonerbaH-Index: 27
view all 45 authors...
Background. Three or four cycles of cisplatin-based chemotherapy is the standard neoadjuvant treatment prior to cystectomy in patients with muscle-invasive bladder cancer. Although NCCN guidelines recommend 4 cycles of cisplatin-gemcitabine, three cycles are also commonly administered in clinical practice. In this multicenter retrospective study, we assessed a large and homogenous cohort of patients with urothelial bladder cancer (UBC) treated with three or four cycles of neoadjuvant cisplatin-g...
Source
INTRODUCTION Radical cystectomy (RC) with bilateral pelvic lymph node dissection (PLND) is a complex surgical procedure, associated with substantial perioperative complications. Previous studies suggested reserving it to high-volume centers in order to improve oncological and perioperative outcomes. However, only limited data exist regarding low-volume centers with highly experienced surgeons. We aimed to assess oncological and perioperative outcomes after RC performed by experienced surgeons in...
Source
Aim: To investigate the prognostic role of neutrophil percentage-to-albumin ratio (NPAR) in muscle-invasive bladder cancer (MIBC) patients treated with neoadjuvant chemotherapy (NAC) and radical cy...
Source
Abstract Background Correct identification of variant histologies (VHs) of bladder cancer (BCa) at transurethral resection of the bladder (TURB) could drive the subsequent treatment. Objective To evaluate the concordance in detecting VHs between TURB and radical cystectomy (RC) specimens in BCa patients. Design, setting, and participants We retrospectively analyzed 1881 BCa patients who underwent TURB and subsequent RC at seven tertiary care centers between 1980 and 2018. VHs were classified as ...
Source
#1Carlotta PalumboH-Index: 6
#2Alessandro Antonelli (University of Brescia)H-Index: 30
Last. Alfredo Berruti (University of Brescia)H-Index: 66
view all 13 authors...
BACKGROUND Luteinizing hormone-releasing hormone (LHRH)-agonists in prostate cancer (PCa) patients induce sarcopenic obesity. The effect of LHRH-antagonist on body composition has never been explored. We evaluated changes in fat (FBM) and lean body mass (LBM) in PCa patients undergoing Degarelix. METHODS This is a single-center prospective study, enrolling 29 non-metastatic PCa patients eligible to LHRH-antagonist from 2017 to 2019. All patients received monthly subcutaneous injection of Degarel...
1 CitationsSource
#1Luca AfferiH-Index: 2
#2Marco MoschiniH-Index: 27
Last. Livio MordasiniH-Index: 14
view all 8 authors...
PURPOSE: To evaluate the trends in risk-group distribution and Pentafecta outcomes in patients treated with nerve-sparing (NS), robot-assisted radical prostatectomy (RARP) in a single low-intermediate volume prostate cancer (PCa) center over a 10-year period. MATERIALS AND METHODS: We queried a prospectively maintained database for patients who underwent NS RARP between 2009 and 2018 in a low-intermediate volume PCa center. Risk-groups were defined according to the D'Amico classification. Pentaf...
1 CitationsSource
#1Luca AfferiH-Index: 2
#2Stefania Zamboni (University of Brescia)H-Index: 9
Last. Marco MoschiniH-Index: 27
view all 27 authors...
PURPOSE: To assess the impact of perioperative chemotherapy on survival in cN+ BCa patients and analyze it according to the pN status. METHODS: A retrospective analysis was conducted on 639 BCa patients with cTanyN1-3M0 BCa treated with radical cystectomy (RC) and bilateral lymph node dissection (LND) with or without perioperative chemotherapy in ten tertiary referral centers from 1990 to 2017. Selected cN+ patients received induction chemotherapy (IC), whereas adjuvant chemotherapy (ACT) was de...
2 CitationsSource
#1Francesco SoriaH-Index: 19
#2Marta Sanchez-Carbayo (UPV/EHU: University of the Basque Country)H-Index: 53
Last. Yair Lotan (UTSW: University of Texas Southwestern Medical Center)H-Index: 107
view all 8 authors...
This consensus aimed to provide a practical update regarding the current role of tissue-based biomarkers in bladder cancer. Their prognostic and predictive role both in non-muscle-invasive (NMIBC) and in muscle-invasive disease (MIBC) has been reviewed with particular focus to their use in clinical practice. In summary, literature information about the prediction of disease recurrence in NMIBC is inconclusive, and even less data is available for prediction of response to intravesical BCG. Concer...
Source
#1Łukasz NowakH-Index: 2
#2Wojciech KrajewskiH-Index: 12
Last. Romuald ZdrojowyH-Index: 14
view all 21 authors...
: To determine whether there are significant differences in oncological outcomes between three different bacillus Calmette–Guerin (BCG) strains used for adjuvant intravesical immunotherapy in patie...
Source